Reactome | Liganded-ALK dimer binds type I ALK-binding TKIs

authored

[InstanceEdit:9725664] Rothfels, Karen, 2021年03月30日

category binding

compartment

created [InstanceEdit:9700663] Rothfels, Karen, 2020年09月16日

dbId 9700662

displayName Liganded-ALK dimer binds type I ALK-binding TKIs

edited

[InstanceEdit:9725664] Rothfels, Karen, 2021年03月30日

eventOf

[Pathway:R-HSA-201556] Signaling by ALK - Homo sapiens

input

isChimeric false

isInDisease false

isInferred false

literatureReference

[LiteratureReference:9671447] Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases
[LiteratureReference:9699633] Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition
[LiteratureReference:9702247] Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases
[LiteratureReference:9702250] Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond
[LiteratureReference:9702256] Crizotinib in anaplastic large-cell lymphoma
[LiteratureReference:9702293] Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib
[LiteratureReference:9700317] ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression
[LiteratureReference:9702216] Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
[LiteratureReference:9700339] Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors
[LiteratureReference:9700357] Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma
[LiteratureReference:9702309] The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models
[LiteratureReference:9702243] Ceritinib in ALK-rearranged non-small-cell lung cancer
[LiteratureReference:9702281] Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer
[LiteratureReference:9699697] Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK
[LiteratureReference:9699768] Role and targeting of anaplastic lymphoma kinase in cancer
[LiteratureReference:9843068] The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status
[LiteratureReference:9843025] IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma
[LiteratureReference:9717312] Targeting ALK: Precision Medicine Takes on Drug Resistance

maxDepth 1

modified [InstanceEdit:10680101] Weiser, Joel, 2025年08月27日

name

Liganded-ALK dimer binds type I ALK-binding TKIs

orthologousEvent

output

[Complex:R-HSA-9700592] ALK dimer:ligand:type I ALK binding TKI [plasma membrane]

precedingEvent

previousReviewStatus [ReviewStatus:9821384] two stars

releaseDate 2021年06月09日

reviewStatus [ReviewStatus:9821382] five stars

reviewed

schemaClass Reaction

species

[Species:48887] Homo sapiens

stId R-HSA-9700662

summation

[Summation:9702326] ALK can be bound and inhibited by type I tyrosine kinase inh...

updateTrackers

[UpdateTracker:9853239] Update Tracker - [Reaction:9700662] Liganded-ALK dimer binds type I ALK-binding TKIs - v87:[addLiteratureReference, add_removeInput, modifyText]

Reactome Pathway Database

Reactome Pathway Database

Liganded-ALK dimer binds type I ALK-binding TKIs Show undefined attributes

Referrals

Cite Us!

Download As: